Aldosterone Synthase Inhibition with or Without Background Sodium Glucose Cotransporter 2 Inhibition in CKD: A Phase II Clinical Trial
Katherine R. Tuttle(Providence Regional Medical Center Everett), Peter Rossing(Steno Diabetes Centers), Zhichao Sun(Boehringer Ingelheim (Japan)), Lisa Cronin(Boehringer Ingelheim (Germany)), Sibylle J. Hauske(Heidelberg University), Dick de Zeeuw(University Medical Center Groningen), Hiddo J.L. Heerspink(University Medical Center Groningen)
Cited by 1
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k